CA2884405C - Composition of hmb and atp and methods of use - Google Patents
Composition of hmb and atp and methods of use Download PDFInfo
- Publication number
- CA2884405C CA2884405C CA2884405A CA2884405A CA2884405C CA 2884405 C CA2884405 C CA 2884405C CA 2884405 A CA2884405 A CA 2884405A CA 2884405 A CA2884405 A CA 2884405A CA 2884405 C CA2884405 C CA 2884405C
- Authority
- CA
- Canada
- Prior art keywords
- hmb
- atp
- animal
- composition
- strength
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title abstract description 36
- 241001465754 Metazoa Species 0.000 claims abstract description 32
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims description 154
- 210000003205 muscle Anatomy 0.000 claims description 50
- 230000001965 increasing effect Effects 0.000 claims description 39
- 239000002253 acid Substances 0.000 claims description 23
- 150000003839 salts Chemical group 0.000 claims description 8
- 239000011885 synergistic combination Substances 0.000 claims description 7
- 230000008901 benefit Effects 0.000 claims description 6
- -1 elixir Substances 0.000 claims description 5
- 150000002596 lactones Chemical class 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000013270 controlled release Methods 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 230000000699 topical effect Effects 0.000 claims description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims 11
- 239000004531 microgranule Substances 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract description 8
- 206010028311 Muscle hypertrophy Diseases 0.000 abstract description 5
- 230000012042 muscle hypertrophy Effects 0.000 abstract description 5
- 230000006872 improvement Effects 0.000 abstract description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 145
- 229960001456 adenosine triphosphate Drugs 0.000 description 143
- 230000009469 supplementation Effects 0.000 description 47
- 238000012549 training Methods 0.000 description 41
- 239000000902 placebo Substances 0.000 description 32
- 229940068196 placebo Drugs 0.000 description 32
- 230000000694 effects Effects 0.000 description 20
- 238000000692 Student's t-test Methods 0.000 description 18
- 238000012353 t test Methods 0.000 description 18
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 16
- 102000004420 Creatine Kinase Human genes 0.000 description 15
- 108010042126 Creatine kinase Proteins 0.000 description 15
- 238000011084 recovery Methods 0.000 description 15
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 12
- 208000029549 Muscle injury Diseases 0.000 description 11
- 235000015872 dietary supplement Nutrition 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 230000003247 decreasing effect Effects 0.000 description 10
- 230000017531 blood circulation Effects 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 8
- 229960000890 hydrocortisone Drugs 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 238000001990 intravenous administration Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 108010074051 C-Reactive Protein Proteins 0.000 description 7
- 102100032752 C-reactive protein Human genes 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 7
- 239000003925 fat Substances 0.000 description 7
- 230000017854 proteolysis Effects 0.000 description 7
- BKAJNAXTPSGJCU-UHFFFAOYSA-N 4-methyl-2-oxopentanoic acid Chemical group CC(C)CC(=O)C(O)=O BKAJNAXTPSGJCU-UHFFFAOYSA-N 0.000 description 6
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 159000000007 calcium salts Chemical class 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 229960003604 testosterone Drugs 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 210000003314 quadriceps muscle Anatomy 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 229960005305 adenosine Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Chemical compound CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 238000010988 intraclass correlation coefficient Methods 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 230000024883 vasodilation Effects 0.000 description 4
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 102000008934 Muscle Proteins Human genes 0.000 description 3
- 108010074084 Muscle Proteins Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 102000000033 Purinergic Receptors Human genes 0.000 description 3
- 108010080192 Purinergic Receptors Proteins 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 235000012054 meals Nutrition 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102100026992 Dermcidin Human genes 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101000911659 Homo sapiens Dermcidin Proteins 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000001351 cycling effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000002414 leg Anatomy 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000007968 orange flavor Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 230000025175 skeletal muscle hypertrophy Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000015580 Increased body weight Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 230000008649 adaptation response Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 150000001844 chromium Chemical class 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000009223 counseling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MWEQTWJABOLLOS-AZGWGOJFSA-L disodium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O MWEQTWJABOLLOS-AZGWGOJFSA-L 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 229940082150 encore Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 229960001123 epoprostenol Drugs 0.000 description 1
- 230000002270 ergogenic effect Effects 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000297 inotrophic effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 108700025647 major vault Proteins 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- QCAWEPFNJXQPAN-UHFFFAOYSA-N methoxyfenozide Chemical compound COC1=CC=CC(C(=O)NN(C(=O)C=2C=C(C)C=C(C)C=2)C(C)(C)C)=C1C QCAWEPFNJXQPAN-UHFFFAOYSA-N 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000008345 muscle blood flow Effects 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000036513 peripheral conductance Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000013105 post hoc analysis Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001696 purinergic effect Effects 0.000 description 1
- 238000013102 re-test Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004648 relaxation of smooth muscle Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014268 sports nutrition Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000025366 tissue development Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698919P | 2012-09-10 | 2012-09-10 | |
| US61/698,919 | 2012-09-10 | ||
| PCT/US2013/059039 WO2014040067A1 (en) | 2012-09-10 | 2013-09-10 | Composition of hmb and atp and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2884405A1 CA2884405A1 (en) | 2014-03-13 |
| CA2884405C true CA2884405C (en) | 2021-03-30 |
Family
ID=50237697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2884405A Active CA2884405C (en) | 2012-09-10 | 2013-09-10 | Composition of hmb and atp and methods of use |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US10092590B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2892522A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6258943B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105025891B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013312113B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015005199B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2884405C (cg-RX-API-DMAC7.html) |
| DK (1) | DK3733171T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2970283T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3733171T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE065064T2 (cg-RX-API-DMAC7.html) |
| PL (1) | PL3733171T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3733171T (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014040067A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2018014407A (es) * | 2016-05-25 | 2019-02-21 | Tsi Group Ltd | Estabilizacion de formulaciones de acido beta-hidroxiisovalerico en capsulas de gel blando. |
| US10888576B2 (en) * | 2018-10-08 | 2021-01-12 | Metabolic Technologies, Inc. | Composition of HMB and ATP and methods of use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5028440A (en) | 1990-01-30 | 1991-07-02 | Iowa State University Research Foundation, Inc. | Method of raising meat producing animals to increase lean tissue development |
| US4992470A (en) | 1990-02-08 | 1991-02-12 | Iowa State University Research Foundation, Inc. | Method of enhancing immune response of mammals |
| CA2142314C (en) | 1992-09-16 | 1999-06-01 | Steven L. Nissen | Method of reducing blood levels of total cholesterol and low-density lipoprotein cholesterol |
| US5348979A (en) | 1992-12-23 | 1994-09-20 | Iowa State University Research Foundation Inc. | Method of promoting nitrogen retention in humans |
| US6031000A (en) | 1998-06-23 | 2000-02-29 | Iowa State University Research Foundation, Inc. | Composition comprising β-hydroxy-β-methylbutyric acid and at least one amino acid and methods of use |
| JP4010390B2 (ja) * | 1999-09-20 | 2007-11-21 | 明治乳業株式会社 | 免疫賦活化組成物 |
| US7629329B2 (en) * | 2001-06-04 | 2009-12-08 | Tsi Health Sciences, Inc. | Method for increasing muscle mass and strength through administration of adenosine triphosphate |
| US20050027005A1 (en) * | 2003-08-02 | 2005-02-03 | Matthias Boldt | Nutrient compositions and methods for sustenance and promotion of positive metabolic energy levels in a targeted manner |
| US20050215640A1 (en) * | 2004-03-26 | 2005-09-29 | Baxter Jeffrey H | HMB compositions and uses thereof |
| US20060083793A1 (en) * | 2004-09-29 | 2006-04-20 | Gardiner Paul T | Nutritional composition for promoting muscle performance and acting as hydrogen (H+) blocker |
| US20060073891A1 (en) * | 2004-10-01 | 2006-04-06 | Holt Timothy M | Display with multiple user privacy |
| KR101299885B1 (ko) * | 2005-05-27 | 2013-08-23 | 코와 가부시키가이샤 | 피로 회복을 위한 의약 |
| WO2007108071A1 (ja) * | 2006-03-17 | 2007-09-27 | Pharma Foods International Co., Ltd. | 抗ストレス組成物及びそれを含有する飲食品 |
| PL2381784T3 (pl) * | 2008-12-09 | 2019-01-31 | Metabolic Technologies, Inc. | Interwencyjny produkt odżywczy w celu poprawy funkcji i siły mięśni |
| DE102009052640A1 (de) | 2009-11-10 | 2011-05-12 | Linde-Lkca-Dresden Gmbh | Verfahren und Vorrichtung zur Gaswäsche |
| WO2011075741A1 (en) * | 2009-12-18 | 2011-06-23 | Metabolic Technologies, Inc. | Improved method of administering beta-hydroxy-beta-methylbutyrate (hmb) |
-
2013
- 2013-09-10 ES ES20169493T patent/ES2970283T3/es active Active
- 2013-09-10 AU AU2013312113A patent/AU2013312113B2/en active Active
- 2013-09-10 PT PT201694932T patent/PT3733171T/pt unknown
- 2013-09-10 DK DK20169493.2T patent/DK3733171T3/da active
- 2013-09-10 WO PCT/US2013/059039 patent/WO2014040067A1/en not_active Ceased
- 2013-09-10 CN CN201380058560.6A patent/CN105025891B/zh active Active
- 2013-09-10 BR BR112015005199-5A patent/BR112015005199B1/pt active IP Right Grant
- 2013-09-10 FI FIEP20169493.2T patent/FI3733171T3/fi active
- 2013-09-10 CA CA2884405A patent/CA2884405C/en active Active
- 2013-09-10 PL PL20169493.2T patent/PL3733171T3/pl unknown
- 2013-09-10 EP EP13835631.6A patent/EP2892522A4/en not_active Ceased
- 2013-09-10 JP JP2015531321A patent/JP6258943B2/ja active Active
- 2013-09-10 HU HUE20169493A patent/HUE065064T2/hu unknown
- 2013-09-10 EP EP20169493.2A patent/EP3733171B1/en active Active
- 2013-09-10 US US14/023,162 patent/US10092590B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2884405A1 (en) | 2014-03-13 |
| EP2892522A1 (en) | 2015-07-15 |
| ES2970283T3 (es) | 2024-05-27 |
| JP2015527408A (ja) | 2015-09-17 |
| EP3733171A1 (en) | 2020-11-04 |
| EP2892522A4 (en) | 2016-01-20 |
| JP6258943B2 (ja) | 2018-01-10 |
| EP3733171B1 (en) | 2023-10-25 |
| AU2013312113B2 (en) | 2018-08-02 |
| BR112015005199A2 (pt) | 2017-07-04 |
| PL3733171T3 (pl) | 2024-03-18 |
| CN105025891B (zh) | 2020-01-21 |
| BR112015005199B1 (pt) | 2022-09-06 |
| DK3733171T3 (da) | 2024-01-29 |
| US10092590B2 (en) | 2018-10-09 |
| FI3733171T3 (fi) | 2024-01-24 |
| AU2013312113A1 (en) | 2015-03-26 |
| US20140080781A1 (en) | 2014-03-20 |
| HUE065064T2 (hu) | 2024-05-28 |
| WO2014040067A1 (en) | 2014-03-13 |
| HK1217087A1 (zh) | 2016-12-23 |
| CN105025891A (zh) | 2015-11-04 |
| PT3733171T (pt) | 2024-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Varanoske et al. | Effects of β-alanine supplementation and intramuscular carnosine content on exercise performance and health | |
| Fitschen et al. | Efficacy of β-hydroxy-β-methylbutyrate supplementation in elderly and clinical populations | |
| Bemben et al. | Creatine supplementation and exercise performance: recent findings | |
| JP5762396B2 (ja) | 糖尿病療法の支援のためのα−ケト酸を含有する栄養補助剤 | |
| CA3087694A1 (en) | Compositions and methods of use of .beta.hydroxy-.beta.-methylbutyrate (hmb) associated witth intermittent fasting | |
| US20150366901A1 (en) | Methods of Treating Heart Failure | |
| CA2884405C (en) | Composition of hmb and atp and methods of use | |
| US10888576B2 (en) | Composition of HMB and ATP and methods of use | |
| McDonough | Oral creatine hydrochloride supplementation: acute effects on submaximal, intermittent bouts of bench press and vertical jump exercises | |
| US20160184248A1 (en) | Compositions and methods of use of -hydroxy-methylbutyrate (hmb) resulting in an acute endocrine response | |
| HK1217087B (zh) | Hmb和atp的组合物及使用方法 | |
| Turpin | Therapeutic role of dietary nitrates on cardiorespiratory function in cancer survivors | |
| Osmond | The Effects of Leucine-Enriched Branched-Chain Amino Acid Supplementation on Exercise-Induced Skeletal Muscle Damage | |
| Kawecka et al. | Creatine supplementation: facts and myths | |
| US20240299435A1 (en) | Compositions containing adenosine triphosphate (atp) and methods of use for cognitive function | |
| Arney | Mechanisms of Fatigability in Individuals With Prediabetes and the Effect of Dietary Nitrate Supplementation | |
| Đuric et al. | The effects of subchronic intake of magnesium hydrocarbonate-rich mineral water on body weight and cardiovascular variables in rats with streptozotocin: Induced diabetes | |
| US20210113501A1 (en) | Method of administering beta-hydroxy-beta-methylbutyrate (hmb) | |
| Frost III | Recovery dynamics in master and aged athletes | |
| Boyle | Effects of Chronic Ingestion of L-arginine alpha ketoglutarate Combined With Creatine monohydrate on Anaerobic Performance in Strength-Trained Athletes | |
| Fitschen | Efficacy of beta-hydroxy-beta-methylbutyrate (HMB) supplementation in hemodialysis patients | |
| Sakkas et al. | Creatine Fails to Augment the Benefits from Resistance Training in Patients with HIV | |
| Porcelli | Functional evaluation of muscle oxidative metabolism in metabolic myophaties. A cross-talk between exercise physiology and clinical medicine | |
| Machin | The effects of polyphenol supplementation on muscular strength, power, and soreness following eccentric exercise | |
| Hogwood et al. | Sex Differences in the Effects of Inorganic Nitrate Supplementation On Exercise Economy 1 and Endurance Capacity in Healthy Young Adults 2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20180405 |